Coherent's (US) urology laser approved in Japan:
This article was originally published in Clinica
The Japanese Ministry of Health and Welfare has granted approval to Coherent (US) for use of the VersaPulse holmium laser to destroy urinary stones. The company says it is the first approval for this procedure in Japan using a solid-state laser. The product application was filed in May 1993 using data from clinical trials conducted at Kurume University Medical School and Nara Medical University. Japan is Coherent's largest potential market for holmium laser lithotripsy, according to Peter Falzon, manager of Coherent Japan. It is the world leader in high technology urinary stone management with over 500 extracorporeal shockwave lithotripter installations.
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.